NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

Yes, great results in a new, significant indication, even if there is still a long way to go for value to be realized. The Japanese market will help in the intermediate term, and, IMO, the fact that they aren’t targeting oncology is a major, if not decisive, advantage from an investment perspective. Time will tell on that front.

The ARDS results also confirm that cell approaches are the way to go in treating diseases with complex, interactive pathways versus the single target approaches (doomed to fail in a curative sense in most cases, IMO).